ID ICC2 AC CVCL_VV27 DR cancercelllines; CVCL_VV27 DR Cell_Model_Passport; SIDM01804 DR DepMap; ACH-001842 DR Wikidata; Q94313313 RX PubMed=27231123; RX PubMed=35640676; RX PubMed=39026794; CC Part of: Biliary tract cancer cell line atlas. CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Doubling time: 3 days (Direct_author_submission). CC Omics: Genomics; Whole exome sequencing. CC Miscellaneous: Doubling time and age/sex of donor from personal communication of El-Bardeesy, Nabeel. CC Derived from site: In situ; Liver; UBERON=UBERON_0002107. ST Source(s): DepMap=ACH-001842 ST Amelogenin: X ST CSF1PO: 12 ST D13S317: 8,11 ST D16S539: 11,12 ST D18S51: 21 ST D21S11: 31,31.2 ST D3S1358: 14 ST D5S818: 12,14 ST D7S820: 8 ST D8S1179: 13 ST FGA: 22,25 ST Penta D: 10,13 ST Penta E: 14 ST TH01: 8,9 ST TPOX: 9,12 ST vWA: 14 DI NCIt; C35417; Intrahepatic cholangiocarcinoma DI ORDO; Orphanet_70567; Cholangiocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Female AG 66Y CA Cancer cell line DT Created: 24-05-19; Last updated: 10-04-25; Version: 13 // RX PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737; RA Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., RA Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., RA Greninger P., McDermott U., Garnett M.J., Jenkins R.L., RA Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., RA Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., RA Bardeesy N.M.; RT "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity RT and SRC dependence in intrahepatic cholangiocarcinoma."; RL Cancer Discov. 6:727-739(2016). // RX PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155; RA Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., RA Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., RA Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.; RT "Development and characterization of human primary cholangiocarcinoma RT cell lines."; RL Am. J. Pathol. 192:1200-1217(2022). // RX PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448; RA Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L., RA Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J., RA Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L., RA Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J., RA Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E., RA Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W., RA Vazquez F., Getz G., Bardeesy N.M.; RT "Generation of a biliary tract cancer cell line atlas reveals RT molecular subtypes and therapeutic targets."; RL bioRxiv 2024:07.04.601970-07.04.601970(2024). //